DHX38 enhances proliferation, metastasis, and EMT progression in NSCLC through the G3BP1-mediated MAPK pathway
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DHX38 enhances proliferation, metastasis, and EMT progression in NSCLC through the G3BP1-mediated MAPK pathway
Authors
Keywords
-
Journal
CELLULAR SIGNALLING
Volume -, Issue -, Pages 110962
Publisher
Elsevier BV
Online
2023-11-05
DOI
10.1016/j.cellsig.2023.110962
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma
- (2023) Zeru Li et al. PLoS Genetics
- Retinitis pigmentosa-linked mutation in DHX38 modulates its splicing activity
- (2022) Mina Obuća et al. PLoS One
- EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities
- (2022) Silvia La Monica Cells
- Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
- (2022) Reinhard Dummer et al. LANCET ONCOLOGY
- FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer
- (2022) Yufei Long et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A renewed concept on the MAPK signaling pathway in cancers: Polyphenols as a choice of therapeutics
- (2022) Juhaer Anjum et al. PHARMACOLOGICAL RESEARCH
- Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
- (2022) Paolo A Ascierto et al. LANCET ONCOLOGY
- MEK inhibitors for the treatment of non-small cell lung cancer
- (2021) Jing Han et al. Journal of Hematology & Oncology
- Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa‐miR‐6887‐3p
- (2021) Haixia Li et al. Cancer Communications
- RAF-MEK-ERK pathway in cancer evolution and treatment
- (2021) Rahim Ullah et al. SEMINARS IN CANCER BIOLOGY
- Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
- (2021) J. Remon et al. ANNALS OF ONCOLOGY
- Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression
- (2021) Elmira Roshani Asl et al. LIFE SCIENCES
- Research Progress on the Structure and Function of G3BP
- (2021) Weifang Kang et al. Frontiers in Immunology
- Anticancer drug resistance: An update and perspective
- (2021) Ruth Nussinov et al. DRUG RESISTANCE UPDATES
- HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer
- (2021) Yiwei Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- STOML2 interacts with PHB through activating MAPK signaling pathway to promote colorectal Cancer proliferation
- (2021) Wenhui Ma et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Revisiting neoadjuvant therapy in non-small-cell lung cancer
- (2021) Stephanie P L Saw et al. LANCET ONCOLOGY
- G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer
- (2021) Chandrani Mukhopadhyay et al. Nature Communications
- The splicing factor DHX38/PRP16 is required for ovarian clear cell carcinoma tumorigenesis, as revealed by a CRISPR‐Cas9 screen
- (2021) Brandon Cona et al. FEBS Open Bio
- Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
- (2020) J. Mazieres et al. ANNALS OF ONCOLOGY
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
- (2020) Ufuk Degirmenci et al. Cells
- G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble Stress Granules
- (2020) Peiguo Yang et al. CELL
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
- (2020) Jimin Yuan et al. Journal of Hematology & Oncology
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
- (2020) Evgeny N. Imyanitov et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Lung cancer
- (2020) Herb Brody NATURE
- KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
- (2019) Helen Adderley et al. EBioMedicine
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- Targeting the ERK Signaling Pathway in Melanoma
- (2019) Paola Savoia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance
- (2019) Micol Eleonora Fiori et al. Molecular Cancer
- Targeting ERK1/2 protein-serine/threonine kinases in human cancers
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
- (2019) Kathryn C. Arbour et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- Telmisartan inhibits oxalate and calcium oxalate crystal-induced epithelial-mesenchymal transformation via PPAR-γ-AKT/STAT3/p38 MAPK-Snail pathway
- (2019) Yadong Liu et al. LIFE SCIENCES
- A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53
- (2018) Chao Mao et al. CANCER RESEARCH
- HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway
- (2018) Lu Chen et al. Cell Death & Disease
- The roles and mechanisms of G3BP1 in tumour promotion
- (2018) Cong-Hui Zhang et al. JOURNAL OF DRUG TARGETING
- G3BP1 promotes DNA binding and activation of cGAS
- (2018) Zhao-Shan Liu et al. NATURE IMMUNOLOGY
- EMT Transition States during Tumor Progression and Metastasis
- (2018) Ievgenia Pastushenko et al. TRENDS IN CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now